Clinical TrialJun 1, 2026, 07:03 AM
Invivyd Completes Enrollment for Phase 3 DECLARATION COVID-19 Trial
AI Summary
Invivyd, Inc. announced the completion of enrollment for its Phase 3 DECLARATION clinical trial evaluating VYD2311, an investigational monoclonal antibody for the prevention of symptomatic COVID-19. The trial, which includes both single and monthly intramuscular dosing arms, was upsized by approximately 500 subjects following a pre-specified sample size re-estimation. Top-line results for the trial remain on track for approximately late Q3 2026.
Key Highlights
- Invivyd completed enrollment for its Phase 3 DECLARATION trial of VYD2311.
- VYD2311 is an investigational monoclonal antibody for symptomatic COVID-19 prevention.
- The trial evaluates single and monthly intramuscular doses of VYD2311.
- Sample size was re-estimated, adding approximately 500 additional subjects.
- Total enrollment for the DECLARATION trial is approximately 2,400 participants.
- Top-line results for the trial are expected in approximately late Q3 2026.
- VYD2311 aims to provide strong protection from COVID-19 for three months and beyond.
Price Impact
More from IVVD